Last checked at 23 Apr 2018 07:00
23 April 2018
Oncimmune Holdings plc
("Oncimmune" or the "Company")
PERSONS DISCHARGING MANAGER RESPONSIBILITIES (PDMR) NOTIFICATION
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces that on 22 April 2018, share options over 493,531 £0.01 ordinary shares of the Company were awarded to a director (who is a PDMR), staff and a consultant under the Company's 2016 Share Option Plan (an amalgamation of the Company's 2005 and 2007 Share Option Plans) and the USA Incentive Stock Option Plan.
Name | Position | Number of Share Options Awarded | Exercise price per Share | Percentage of issued ordinary share capital |
Adam Hill | Chief Medical Officer and Chief Strategy Officer | 396,825 | £1.26 | 0.58% |
Other employees and a consultant (not directors or PDMR's) | 96,706 | £1.26 | 0.14% |
The options are subject to the rules of the 2016 Share Option Plan and the USA Incentive Stock Option Plan and vest in five equal annual parts, the first fifth vesting on 22 April 2019 and each year thereafter for a further four years, subject to continued employment. All these options are exercisable at £1.26 pence, being the mid-market price of the Company's ordinary shares at the close of day on 20 April 2018.
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Broker)
Giles Balleny
+44 (0) 203 829 5000
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville
oncimmune@consilium-comms.com
+44 (0) 20 3709 5708
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name
| Adam Hill | ||||
2 | Reason for the notification | |||||
a) | Position/status
| Chief Medical Officer and Chief Strategy Officer | ||||
b) | Initial notification/Amendment
| Initial Notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Oncimmune Holdings plc | ||||
b) | LEI | 213800HCYIWT6YPI1I02 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument
Identification code | options over 1p ordinary shares - 2016 Share Option Plan
ISIN GB00BYQ94H38 | ||||
b) | Nature of the transaction
| Grant of options over ordinary shares | ||||
c) | Price(s) and volume(s)
|
| ||||
d) | Aggregated information
|
| ||||
e) | Date of the transaction
| 20 April 2018 | ||||
f) | Place of the transaction
| N/A | ||||